From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Legal status
CAS number 119431-25-3 N
ATC code None
PubChem CID 60703
ChemSpider 54708 YesY
Synonyms Eliprodil
Chemical data
Formula C20H23ClFNO 
Mol. mass 347.854 g/mol
 N (what is this?)  (verify)

Eliprodil (SL-82.0715) is a drug which acts as an NMDA antagonist, binding to the polyamine modulatory site.[1] It has neuroprotective and anticonvulsant effects in animal studies,[2] but does not support self-administration or substitute for phencyclidine,[3] and does not produce sedation or amnesia.[4] It was researched for the treatment of stroke[5] and epilepsy[6] but human trials failed to show clear beneficial effects.[7]


  1. ^ Dereń-Wesołek, A; Maj, J (1993). "Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex". Polish journal of pharmacology 45 (5–6): 467–80. PMID 7912135. 
  2. ^ Toulmond, S; Serrano, A; Benavides, J; Scatton, B (1993). "Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window". Brain Research 620 (1): 32–41. doi:10.1016/0006-8993(93)90267-Q. PMID 8402196. 
  3. ^ Balster, RL; Nicholson, KL; Sanger, DJ (1994). "Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats". Drug and alcohol dependence 35 (3): 211–6. doi:10.1016/0376-8716(94)90076-0. PMID 7956750. 
  4. ^ Patat, A; Molinier, P; Hergueta, T; Brohier, S; Zieleniuk, I; Danjou, P; Warot, D; Puech, A (1994). "Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist". International clinical psychopharmacology 9 (3): 155–62. doi:10.1097/00004850-199409000-00003. PMID 7814824. 
  5. ^ Reyes, M; Reyes, A; Opitz, T; Kapin, MA; Stanton, PK (1998). "Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage". Brain Research 782 (1–2): 212–8. doi:10.1016/S0006-8993(97)01280-8. PMID 9519265. 
  6. ^ Kohl, BK; Dannhardt, G (2001). "The NMDA receptor complex: a promising target for novel antiepileptic strategies". Current medicinal chemistry 8 (11): 1275–89. doi:10.2174/0929867013372328. PMID 11562266. 
  7. ^ Ikonomidou, C; Turski, L (2002). "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?". Lancet neurology 1 (6): 383–6. doi:10.1016/S1474-4422(02)00164-3. PMID 12849400.